Share this article
Share this article
ResearchAndMarkets.com s offering.
The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase.
Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, among others. The n
Germany
Japan
United-states
India
United-kingdom
Israel
Belgium
China
Portugal
Ireland
Russia
Dublin